HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

volagidemab

IgG2 monoclonal antibody against the human glucagon receptor for treatment of type I diabetes

Also Known As:

AMG-477; REMD-477

Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bautista, Edgar: 1 article (01/2018)
2.	Boeder, Schafer: 1 article (01/2018)
3.	Cava, Edda: 1 article (01/2018)
4.	Cavaiola, Tricia S: 1 article (01/2018)
5.	Henry, Robert R: 1 article (01/2018)
6.	Klein, Samuel: 1 article (01/2018)
7.	Levin, Michelle: 1 article (01/2018)
8.	McMillan, John: 1 article (01/2018)
9.	Pettus, Jeremy: 1 article (01/2018)
10.	Reeds, Dominic: 1 article (01/2018)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/01/2023 - "Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial." 10/01/2022 - "Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial." 01/01/2018 - "no. NCT02715193, clinicaltrials.gov) was to study the efficacy and safety of REMD-477, a glucagon receptor antagonist, in type 1 diabetes. "
2.	Hypoglycemia (Reactive Hypoglycemia) 10/01/2022 - "No increase in hypoglycemia was observed with volagidemab therapy; however, increases in serum transaminases, low-density lipoprotein (LDL)-cholesterol and blood pressure were observed. "

Related Drugs and Biologics

1.	Glucagon Receptors (Glucagon Receptor)
2.	LDL Cholesterol
3.	LDL Lipoproteins (beta Lipoproteins)
4.	Transaminases (Aminotransferases)

Related Therapies and Procedures

1.	Therapeutics